Healthy allogeneic donors, who were treated with G-CSF and underwent peripheral blood haematopoietic precursor collection at our Institution, were enrolled in a short-and long-term haematological surveillance protocol for a 5-7-year period. To date, 94 donors have been assessed with a mean follow-up of 30 months (4-84); for 30 subjects, the follow-up is X48 months. During G-CSF administration, 23/94 donors showed a significant platelet count decrease from the baseline. Pre-apheresis platelet decrement correlated with the total G-CSF dose administered, baseline platelet level and donor age. Normal platelet counts returned within 4-8 months. PMN and/or lymphocyte lower values were observed in 55/94 donors 2 weeks after G-CSF administration, with mean drops from the baseline of 40 and 36% for PMN and lymphocytes, respectively. The PMN decrease correlated inversely with donor age, as younger donors were more affected than older ones, whereas the lymphocyte decrease correlated directly with the total blood volumes processed in the apheresis courses, in particular for donors subjected to large volume leukaphereses. Long-term observation showed moderate neutrophil reduction (25% count drop from the baseline) in four of the 30 donors observed for four years or more. 14 donors showed persistent, slight lymphocytopenia (mean drop of 13%) until the third year, with recovery in the fourth year of follow-up.
adverse side effects
The efficacy of G-CSF in mobilizing the bone-marrow haematopoietic precursors has been extensively demonstrated both in patients and in normal donors. [1] [2] [3] However, there are concerns about G-CSF use in healthy people due to potential severe adverse side effects, such as tetrameric alterations on myeloid precursors 4 and acute myelogenous leukemia 5 described and correlated with the use of G-CSF. The shortterm clinical adverse side effects are well known, and most frequently described as mild to moderate, 6 although isolated cases of severe clinical involvement have been published. [7] [8] [9] The long-term safety of the G-CSF use in healthy donors is however not well documented and to date few results are available. [10] [11] [12] In view of this, additional data are needed to exclude long-term bone marrow damage. 13 The aim of the present prospective study was the haematological evaluation during a 5-year follow-up period in a population of donors treated with G-CSF and subjected to peripheral blood stem cell collection in the Apheresis Unit of our Transfusion Medicine Service.
Donors and collection
From November 1996 to August 2004, 141 healthy donors underwent peripheral blood stem cell (PBSC) collection after G-CSF mobilization, in the Apheresis Unit of the Transfusion Medicine Service of the Sant' Orsola-Malpighi University Polyclinic in Bologna, Italy. All donors were related (ie siblings) to their adult recipients and enrolled after written informed consent according to the Ethical Committee of our Hospital and national and international guidelines for allogeneic bone marrow donations. [14] [15] [16] In total, 10 donors received lenograstim, 12 mg/kg body weight (b.w.) daily, for 6 days, while the others were treated with 10 mg/kg daily, for 5-7 days, as shown in Tables 1 and 2 . PBSC collection started as soon as the detectable circulating CD34 þ cells exceeded the cutoff value of 20/ml. In total, 165 harvests were performed by means of continuous-flow apheresis equipment. Two donor blood volumes, equivalent to a mean of 1172.5 l were processed in 110 standard procedures performed in 74 donors, while three blood volumes (1874 l) were treated in 55 aphereses carried out in 20 donors, who were poor mobilizers, to optimize the CD34 þ cells collection. The mean CD34 þ cell dose obtained was 5.571.5 Â 10/ 6 per kg of the recipient b.w. with a mean collection efficiency of 61718%.
The collected products were shipped for appropriate manipulation and cryopreservation to the Cell Processing Facility of the Hematology and Medical Oncology Institute, where the allogeneic transplantations were carried out in the Hematopoietic Stem Cells Transplantation Unit.
Short-and long-term hematological surveillance protocol design
Before starting the mobilizing treatment, all donors were exhaustively informed about the G-CSF use in healthy donors and patients and sensitized to the need for a longterm and worldwide collection of follow-up data. For short-term clinical data, a questionnaire reporting symptoms and arbitrary grading of the adverse side effects during the G-CSF administration was given at the first PBSC harvest and on day þ 14, 7 days after the treatment had been concluded. Moreover, donors were asked to inform our service by telephone call or mail about their clinical status in the case of occurrence of relevant diseases, throughout a follow-up period of 5 years. To evaluate hematological parameter modifications, donors were invited to send our service a complete peripheral blood cell evaluation, including a differential white blood cell (WBC) count (i) at day þ 14, (ii) every 4 months during the first year of follow-up, and (iii) once a year for 5 years. Whenever possible and to reduce the incidence of interlaboratory variations, donors were recommended to undergo their hematological analyses in the same centre. Finally, to ensure a complete data collection during the follow-up, we solicited donors yearly by mail or/and telephone calls if they did not send the reports.
All the results collected have been evaluated using a dedicated Excel database. Donors whose complete clinical and hematological data were collected at the scheduled intervals have been included in the present study.
Statistical analysis
Results have been represented as means7s.d. (standard deviation). Comparisons between two groups were performed by the paired t-test or using the Wilcoxon sign ranks test when required. Independent analysis was performed by the unpaired t-test or the Mann-Whitney test for nonparametric data. To compare three or more groups, the Kruskal-Wallis test was employed. Simple regression analysis completed the study. All the tests were performed using StatView software (SAS, Incorporated).
Results

Donor compliance to the surveillance protocol
Up to date, 94 donors are evaluable with a mean follow-up of 30 months (range 4-84). With regard to patient compliance with the surveillance protocol, 47 donors did not consent to the study for various reasons: 12 because they lived abroad, 20 because of discomfort from venipuncture, the others for personal reasons. Finally, despite recurrent solicitations, eight subjects did not send any clinical or hematological data after day þ 14 and were consequently excluded from the present study. Donor distribution per follow-up has been shown in Figure 1 .
Pre-collection clinical and laboratory data. Bone pain, headache and fatigue were the most frequent adverse side effects observed, as shown in Figure 2 . Anti-inflammatory or minor analgesic drugs were used in about half of the cases. All donors were able to complete the mobilizing protocol, without interruption or reduction of the scheduled growth-factor dosage; about 5% of donors were absent from work for more than 7 days.
Lactate dehydrogenase (LDH) and alkaline phosphatase (AP) showed an average of a two-to three-fold increase after G-CSF administration, while analysis of other biochemical parameters did not show significant variations.
Pre-collection hematological data. WBC counts increased six-fold from the baseline (42712 Â 10 3 vs 6.671.2 Â 10 3 /ml, Po0.05). The main increase was due to neutrophils (35712 Â 10 3 vs 3.971 Â 10 3 /ml, Po0.05), while lymphocyte and monocyte counts doubled baseline values.
As the platelet count may be a limiting factor for the leukapheretic procedure, we arbitrarily regarded as significant a drop in the platelet count of X20% from the baseline value. A total of 23 subjects showed a preapheresis platelet mean decrease of 35% (range 21-45) with a mean absolute platelet count of 156710 Â 10 6 vs 231720 Â 10 6 /ml, Po0.05. In these 23 donors, preapheresis platelet count correlated inversely with baseline Simple regression analysis showed an inverse relationship between neutropenia severity and donor age (R 2 ¼ 0.01, P ¼ 0.02) and an unpaired test confirmed that younger donors were more affected than older ones (37710 vs 47710 years, Po0.05, Table 4 ).
As to lymphocytes, an average reduction of 40% (range 12-62) was found in 25 donors, with absolute counts of 1.370.4 Â 10 3 /ml, and values o1.0 Â 10 3 /ml in five donors. A significant, direct correlation was found with total blood volumes processed in the apheresis and a greater lymphopenia was observed in donors subjected to larger harvests (3278 l vs 2472, Po0.05, Table 5 ).
Finally and with regard to platelets, a post-collection platelet count below the normal minimum value of 150 Â 10 6 /ml was detected in 40 donors, who showed mean absolute count of 105719 Â 30 6 vs 233770 Â 10 6 /ml, Po0.05 (Figure 3 ). Platelet counts below 50 Â 10 6 /ml were found in only 10 donors, all subjected to three PBSC harvests characterized by (i) a mean platelet collection efficiency of 48726%, (ii) a mean blood volumes processed of 3278 l.
Post-collection observations after the first year. In total, 67 donors had a mean follow-up of 30 months (range 13-84), and in 30 donors the mean follow-up was 52 months (range 48-84). Lymphopenia persisted beyond 3 years in 14 donors and the count drop was 13% (range 11-25) compared to baseline figures (Figure 4) . Unfortunately, the small number of cases precluded any significant comparison between groups analysed for multiple parameters (data not shown); nevertheless, lymphopenic patients were Follow-up of G-CSF mobilized donors C Tassi et al more frequently females (9 F vs 5 M, P ¼ 0.03). Baseline lymphocyte values were completely recovered 4 years after G-CSF mobilization.
As to neutrophils, an isolated, persistent reduction (À25% of the pre-apheresis values) was detectable after 5 years of follow-up, in four donors ( Figure 5 ). It is difficult to know exactly what might underlie such neutropenia. Autoimmunity, drugs or effects not due to the mobilization and apheretic protocol might be related to this phenomenon, but we have not received this clinical information.
Discussion
Our prospective study, started in 1996, deals with the hematological histories of healthy donors of hematopoietic stem cells subjected to G-CSF mobilization and PBSC collection in a single institution. The aim was to collect and analyse the laboratory data on the trend of recovery of normal, or possibly pathological, hematological parameters during the first year post-donation (short term), and throughout a period of 5 years. Main short-term clinical adverse side effects were similar to those already described. 1 As to the short-term observation, lymphocyte and/or neutrophil reduction from the baseline ranged from 20 to 75% and lymphocytopenia and/or neutropenia were documented in 58.5% of donors.
An absolute, transient neutropenia (PMNo1 Â 10 3 /ml) was detectable for only 4 months in three donors, without any clinical signs. Similar results were published in other studies, 12, 17 and, in agreement with them, we were not able to find a true reason for the G-CSF induced cytopenias; a series of hypotheses might be merely suggested. 18, 19 Our series of donors showed post-G-CSF thrombocytopenia, neutropenia or lymphocytopenia, seeming to originate from (i) mobilizing schedules; (ii) donor state; or the (iii) apheresis procedures. In fact, an isolated and severe neutropenia was more frequently found in younger donors and in subjects treated with G-CSF for more than 5 days. Moreover, the total G-CSF dose administered also seemed to correlate closely with platelet reduction, even though older donors and platelet baseline counts seemed to be related. As regards longer period of observation, neutropenia and lymphocytopenia were found self-limiting and normal values were recorded within 2 years in the majority of donors. Four donors, however, maintain reduced neutrophil counts after 4 years of follow-up. Interestingly, none of these donors reported in telephone interviews significant anamnestic data strictly correlated with the neutropenic status. Other studies on long-term follow-up have been published; 11, 12 however, they are all retrospective. Cavallaro et al 11 show results obtained from different centres and the series of donors are heterogeneous in terms of mobilizing protocols, purpose and modality of the peripheral cell collections. Another study 12 deals with healthy donors submitted to a second mobilizing treatment for the collection of haematopoietic precursors; it should be underlined that this latter is a selected group and clinical and hematological history of these donors might potentially differ from that of 'de novo' treated subjects. Severe functional 20 or genetic alterations 21 have been recently demonstrated in the circulating lymphocytes of normal donors treated with G-CSF. These recent findings and the cases of acute myeloid leukemia occasionally described, suggest care in the use of the growth factor in particular in younger healthy subjects. This was indeed the major point in favour of the choice for a prospective study in our Institute. On the other hand, a prospective study is very difficult, in particular due to low donor compliance, frequently for psychological and personal reasons. In this way, data collection might be incomplete and very timeconsuming. Nevertheless, we are willing to maintain a 5-year long-term surveillance on all donors enrolled until the 2004 year, while we will try to extend the follow-up observation for 10 years in all young donors and in unrelated donors whose G-CSF treatment is in progress in our institution. 
